Neetu Chandra Sharma is a National Writer- Health at Mint. She focuses on themes related to medicine and healthcare, including the healthcare system, alternative medicine, diagnostics, and health and wellness, particularly in the context of India and its business landscape. Neetu's work has been featured in Business Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Neetu Chandra Sharma's coverage primarily focuses on the healthcare and pharmaceutical industry in India. She frequently includes data, press releases, government announcements, and private sector developments in her articles. To effectively reach out to Neetu Chandra Sharma, consider offering access to exclusive data or insights related to the Indian healthcare sector. Additionally, pitches that provide analysis of government policies or initiatives impacting healthcare or pharmaceuticals in India are likely to resonate with her coverage focus.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Neetu Chandra Sharma
Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected to significantly disrupt the pharmaceutical landscape in the country this year. And, the weight management market could reach Rs 3.99 lakh crore by 2032, growing at a CAGR of more than 9%
By: Neetu Chandra Sharma
Deal values Aragen at approximately $1.4 billion, with Quadria acquiring a minority stake through a combination of fresh capital infusion and a partial share sale by existing investors
By: Neetu Chandra Sharma
In a shift in how obesity is understood and treated in India, The Lancet Diabetes & Endocrinology Commission has introduced a new framework for defining and diagnosing the condition.
By: Neetu Chandra Sharma
As India approaches the Union Budget 2025, the healthcare and med-tech industries are pushing for reforms that could reshape the sector, positioning
By: Neetu Chandra Sharma
The trial for the treatment will use non-toxic bacteria to deliver drugs directly into tumours.
By: Neetu Chandra Sharma
The patent expiry of key drugs in 2025-26 will open up additional market space for Indian manufacturers of generics and biosimilars.
By: Neetu Chandra Sharma
The healthcare sector is expected to receive a shot in the arm in Budget 2025-26, with a focus on primary healthcare, digital health, and boosting pharmaceutical manufacturing and research.
By: Neetu Chandra Sharma
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.
Looking to the future, Suven’s Horizon 2 initiative – which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 – is expected to enhance the company’s position in advanced drug modalities.
By: Neetu Chandra Sharma
The World Bank estimates the economic cost of pollution-related illnesses to be 1.4% of India’s GDP annually, highlighting the urgency of transitioning to cleaner energy solutions
(833) 317-6278 
